Skip to main content
SpringerLink
Log in

Polypharmazie in der Behandlung der Schizophrenie

  • Chapter
Polypharmazie in der Behandlung psychischer Erkrankungen

  • 1106 Accesses

Zusammenfassung

Die Frage, ob eine Polypharmazie in der Behandlung der Schizophrenie Vorteile gegenüber einer Monotherapie hat, ist nach wie vor ungeklärt. Die klinische Praxis zeigt jedoch, dass entgegen plausibler Empfehlungen, Einzelsubstanzen optimal einzusetzen, überaus häufig Kombinationstherapien durchgeführt werden (Freudenreich und Goff 2002, Chakos et al. 2006, Faries et al. 2005, Ganguly et al. 2004, Kane 2004). Als eine mögliche Ursache gilt die therapieresistenz, die trotz der Einführung moderner, so genannter atypischer Antipsychotika in bis zu 30% der Fälle festzustellen ist (Naber 2000).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Freudenreich O, Goff DC (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 106 (5): 323–330

    Article  CAS  PubMed  Google Scholar 

  2. Naber D (2000) [Atypical antipsychotics] Nervenarzt 71 (5): 327–328

    Article  CAS  PubMed  Google Scholar 

  3. Stahl SM (1999) Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J Clin Psychiatry 60 (7): 425–426

    CAS  PubMed  Google Scholar 

  4. Linden M, Scheel T, Xaver EF (2004) Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. Hum Psychopharmacol 19 (2): 111–119

    Article  CAS  PubMed  Google Scholar 

  5. Tapp A, Wood AE, Secrest L et al (2003) Combination antipsychotic therapy in clinical practice. Psychiatry Serv 54 (1): 55–59

    Article  Google Scholar 

  6. Keks NA, Altson K, Hope J et al (1999) Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 33 (6): 896–901

    Article  CAS  PubMed  Google Scholar 

  7. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28 (1): 75–84

    PubMed  Google Scholar 

  8. Meltzer H, Kostakoglu A (2004) Combining antipsychotics: is there evidence for efficacy? Psychiatric Times XVII (9)

    Google Scholar 

  9. Brunot A, Lachaux B, Sontag H et al (2002) [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia]. Encephale 28 (2): 129–138

    CAS  PubMed  Google Scholar 

  10. Leslie DL, Rosenheck RA (2001) Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 39 (9): 923–933

    Article  CAS  PubMed  Google Scholar 

  11. Ereshefsky L (1999) Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 60 [Suppl] 10: 20–30

    CAS  PubMed  Google Scholar 

  12. Schumacher JE, Makela EH, Griffin HR (2003) Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 37 (7–8): 951–955

    Article  PubMed  Google Scholar 

  13. Sim K, Su A, Fujii S et al (2004) Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58 (2): 178–183

    Article  PubMed  Google Scholar 

  14. Ito C, Kubota Y, Sato M (1999) A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci [Suppl] 53: 35–40

    Google Scholar 

  15. Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H (2004) A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28 (2): 361–369

    Article  CAS  PubMed  Google Scholar 

  16. Muijen M, Silverstone T (1987) A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 150: 501–504

    Article  CAS  PubMed  Google Scholar 

  17. Oepen G (2002) Polypharmacy in Schizophrenia. In: Ghaemi SN (ed) Polypharmacy in psychiatry. Dekker, New York

    Google Scholar 

  18. Covell NH, Jackson CT, Evans AC, Essock SM (2002) Antipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 28 (1): 17–29

    PubMed  Google Scholar 

  19. Rittmannsberger H, Meise U, Schauflinger K et al (1999) Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 14 (1): 33–40

    Article  CAS  PubMed  Google Scholar 

  20. McCue RE, Waheed R, Urcuyo L (2003) Polypharmacy in patients with schizophrenia. J Clin Psychiatry 64 (9): 984–989

    PubMed  Google Scholar 

  21. Lerner V, Libov I, Kotler M, Strous RD (2004) Combination of “atypical” antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 28 (1): 89–98

    Article  CAS  PubMed  Google Scholar 

  22. Kane JM (2004) Effective long-term management of schizophrenia: real-world Considerations. Lecture APA 2004 New York

    Google Scholar 

  23. Rupnow M, Greenspan A, Kosik-Gonzales C et al (2005) Polypharmacy in schizophrenie: data from a randomized, double-blind study. Abstract presented at the APA 2005 Atlanta

    Google Scholar 

  24. Procyshyn RM, Kennedy NB, Tse G, Thompson B (2001) Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 46 (4): 334–339

    CAS  PubMed  Google Scholar 

  25. Procyshyn RM, Thompson B (2004) Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry 37 (1): 12–17

    Article  CAS  PubMed  Google Scholar 

  26. Godleski LS, Kerler R, Barber JW et al (1989) Multiple versus single antipsychotic drug treatment in chronic psychosis. J Nerv Ment Dis 177 (11): 686–689

    Article  CAS  PubMed  Google Scholar 

  27. Huttunen MO, Tuhkanen H, Haavisto E et al (1996) Low-and standard-dose depot haloperidol combined with targeted oral neuroleptics. Psychiatr Serv 47 (1): 83–85

    CAS  PubMed  Google Scholar 

  28. Peacock L, Gerlach J (1994) Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 55 (2): 44–49

    CAS  PubMed  Google Scholar 

  29. Kennedy NB, Procyshyn RM (2000) Rational antipsychotic polypharmacy. Can J Clin Pharmacol 7 (3): 155–159

    CAS  PubMed  Google Scholar 

  30. Grohmann R, Ruther E, Sassim N, Schmidt LG (1989) Adverse effects of clozapine. Psychopharmacology (Berl) [Suppl] 99: 101–104

    Article  Google Scholar 

  31. Potter WZ, Ko GN, Zhang LD, Yan WW (1989) Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berl) [Suppl] 99: 87–91

    Article  Google Scholar 

  32. Shiloh R, Zemishlany Z, Aizenberg D et al (1997) Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 171: 569–573

    Article  CAS  PubMed  Google Scholar 

  33. Cooke C, de Leon J (1999) Adding other antipsychotics to clozapine. J Clin Psychiatry 60 (10): 710

    CAS  PubMed  Google Scholar 

  34. Allen SA (2000) Effect of chloropromazine and clozapine on plasma concentrations of haloperidol in a patient with schizophrenia. J Clin Pharmacol 40 (11): 1296–1297

    CAS  PubMed  Google Scholar 

  35. Friedman J, Ault K, Powchik P (1997) Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 42 (6): 522–523

    Article  CAS  PubMed  Google Scholar 

  36. Stubbs JH, Haw CM, Staley CJ, Mountjoy CQ (2000) Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine. Acta Psychiatr Scand 102 (5): 390–393

    Article  CAS  PubMed  Google Scholar 

  37. Stahl SM, Grady MM (2004) A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11 (3): 313–327

    Article  CAS  PubMed  Google Scholar 

  38. Josiassen RC, Joseph A, Kohegyi E et al (2005) Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 162 (1): 130–136

    Article  PubMed  Google Scholar 

  39. de Groot IW, Heck AH, van Harten PN (2001) Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J Clin Psychiatry 62 (2): 129–130

    PubMed  Google Scholar 

  40. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI et al (2005) A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 66 (1): 63–72

    PubMed  Google Scholar 

  41. Zink M, Knopf U, Henn FA, Thome J (2004) Combination of clozapine and amisulpride in treatment-resistant schizophrenia — case reports and review of the literature. Pharmacopsychiatry 37 (1): 26–31

    Article  CAS  PubMed  Google Scholar 

  42. Zink M, Mase E, Dressing H (2004) Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol 19 (4): 271–273

    Article  CAS  PubMed  Google Scholar 

  43. Kaye NS (2003) Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 64 (2): 215–216

    PubMed  Google Scholar 

  44. Tyson SC, Devane CL, Risch SC (1995) Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 152 (9): 1401–1402

    CAS  PubMed  Google Scholar 

  45. McCarthy RH, Terkelsen KG (1995) Risperidone augmentation of clozapine. Pharmacopsychiatry 28 (2): 61–63

    Article  CAS  PubMed  Google Scholar 

  46. Henderson DC, Goff DC (1996) Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 57 (9): 395–397

    CAS  PubMed  Google Scholar 

  47. Koreen AR, Lieberman JA, Kronig M, Cooper TB (1995) Cross-tapering clozapine and risperidone. Am J Psychiatry 152 (11): 1690

    CAS  PubMed  Google Scholar 

  48. Godleski LS, Sernyak MJ (1996) Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 153 (5): 735–736

    CAS  PubMed  Google Scholar 

  49. Chong SA, Tan CH, Lee HS (1997) Atrial ectopics with clozapine-risperidone combination. J Clin Psychopharmacol 17 (2): 130–131

    Article  CAS  PubMed  Google Scholar 

  50. Patel JK, Salzman C, Green AI, Tsuang MT (1997) Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. Am J Psychiatry 154 (4): 543–546

    CAS  PubMed  Google Scholar 

  51. Gupta S, Sonnenberg SJ, Frank B (1998) Olanzapine augmentation of clozapine. Ann Clin Psychiatry 10 (3): 113–115

    CAS  PubMed  Google Scholar 

  52. Morera AL, Barreiro P, Cano-Munoz JL (1999) Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand 99 (4): 305–306

    Article  CAS  PubMed  Google Scholar 

  53. Adesanya A, Pantelis C (2000) Adjunctive risperidone treatment in patients with clozapine-resistant schizophrenia. Aust N Z J Psychiatry 34 (3): 533–534

    Article  CAS  PubMed  Google Scholar 

  54. Raju, Kumar R, Khanna S (2001) Clozapine-risperidone combination in treatment-resistant schizophrenia. Aust N Z J Psychiatry 35 (4): 543

    CAS  PubMed  Google Scholar 

  55. Raskin S, Katz G, Zislin Z, Knobler HY, Durst R (2000) Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 101 (4): 334–336

    CAS  PubMed  Google Scholar 

  56. Rhoads E (2000) Polypharmacy of 2 atypical antipsychotics. J Clin Psychiatry 61 (9): 678–680

    CAS  PubMed  Google Scholar 

  57. Taylor CG, Flynn SW, Altman S et al (2001) An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 48 (1): 155–158

    Article  CAS  PubMed  Google Scholar 

  58. Henderson DC, Goff DC, Connolly CE, Borba CP, Hayden D (2001) Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 62 (8): 605–608

    CAS  PubMed  Google Scholar 

  59. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, Christodoulou GN (2002) Toxic interaction between risperidone and clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 26 (2): 407–409

    Article  PubMed  Google Scholar 

  60. Raaska K, Raitasuo V, Neuvonen PJ (2002) Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration. Eur J Clin Pharmacol 58 (9): 587–591

    Article  CAS  PubMed  Google Scholar 

  61. Procyshyn RM, Tse G, Sin O, Flynn S (2002) Concomitant clozapine reduces smoking in patients treated with risperidone. Eur Neuropsychopharmacol 12 (1): 77–80

    Article  CAS  PubMed  Google Scholar 

  62. Agelink MW, Kavuk I, Ak I (2004) Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 161 (5): 924–925

    Article  PubMed  Google Scholar 

  63. Munro J, Matthiasson P, Osborne S et al (2004) Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 110 (4): 292–298

    Article  CAS  PubMed  Google Scholar 

  64. Bacher NM, Kaup BA (1996) Combining risperidone with standard neuroleptics for refractory schizophrenic patients. Am J Psychiatry 153 (1): 137

    CAS  PubMed  Google Scholar 

  65. Terao T, Kojima H (2001) Risperidone addition and psychotic exacerbation. J Neuropsychiatry Clin Neurosci 13 (1): 114–115

    CAS  PubMed  Google Scholar 

  66. Potkin SG, Thyrum PT, Alva G et al (2002) The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 22 (2): 121–130

    Article  CAS  PubMed  Google Scholar 

  67. Chue P, Welch R, Snaterse M (2001) Combination risperidone and quetiapine therapy in refractory schizophrenia. Can J Psychiatry 46 (1): 86–87

    CAS  PubMed  Google Scholar 

  68. Lerner V, Chudakova B, Kravets S, Polyakova I (2000) Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 23 (5): 284–286

    Article  CAS  PubMed  Google Scholar 

  69. Seger A, Lamberti JS (2001) Priapism associated with polypharmacy. J Clin Psychiatry 62 (2): 128

    CAS  PubMed  Google Scholar 

  70. Beelen AP, Yeo KT, Lewis LD (2001) Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being trated with risperidone. Hum Exp Toxicol 20 (4): 215–219

    Article  CAS  PubMed  Google Scholar 

  71. Raskin S, Durst R, Katz G, Zislin J (2000) Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol 20 (5): 500–503

    Article  CAS  PubMed  Google Scholar 

  72. Takhar J (1999) Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine. J Psychiatry Neurosci 24 (3): 248–249

    CAS  PubMed  Google Scholar 

  73. Jarventausta K, Leinonen E (2000) Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. Acta Psychiatr Scand 102 (3): 231–233

    Article  CAS  PubMed  Google Scholar 

  74. Mujica R, Weiden P (2001) Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic. Am J Psychiatry 158 (4): 650–651

    Article  CAS  PubMed  Google Scholar 

  75. Hedges DW, Jeppson KG (2002) New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother 36 (3): 437–439

    Article  PubMed  Google Scholar 

  76. Kotler M, Strous RD, Reznik I et al (2004) Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 19 (1): 23–26

    Article  PubMed  Google Scholar 

  77. Gomberg RF (1999) Interaction between olanzapine and haloperidol. J Clin Psychopharmacol 19 (3): 272–273

    Article  CAS  PubMed  Google Scholar 

  78. Duggal HS (2004) Aripirazole-olanzapine combination for treatment of schizophrenia. Can J Psychiatry 49 (2): 151

    PubMed  Google Scholar 

  79. Zink M, Henn FA, Thome J (2004) Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses 3. Eur Psychiatry 19 (1): 56–58

    Article  PubMed  Google Scholar 

  80. Citrome L, Levine J, Allingham B (2000) Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 51 (5): 634–638

    Article  CAS  PubMed  Google Scholar 

  81. Citrome L, Jaffe A, Levine J, Allingham B (2002) Use of mood stabilizers among patients with schizophrenia, 1994–2001. Psychiatr Serv 53 (10): 1212

    Article  PubMed  Google Scholar 

  82. Wilson WH (1995) Do anticonvulsants hinder clozapine treatment? Biol Psychiatry 37 (2): 132–133

    Article  CAS  PubMed  Google Scholar 

  83. Delva NJ, Letemendia FJ (1982) Lithium treatment in schizophrenia and schizo-affective disorders. Br J Psychiatry 141: 387–400

    Article  CAS  PubMed  Google Scholar 

  84. Donaldson SR, Gelenberg AJ, Baldessarini RJ (1983) The pharmacologic treatment of schizophrenia: a progress report. Schizophr Bull 9 (4): 504–527

    CAS  PubMed  Google Scholar 

  85. Small JG, Kellams JJ, Milstein V, Moore J (1975) A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 132 (12): 1315–1317

    CAS  PubMed  Google Scholar 

  86. Growe GA, Crayton JW, Klass DB, Evans H, Strizich M (1979) Lithium in chronic schizophrenia. Am J Psychiatry 136 (4A): 454–455

    CAS  PubMed  Google Scholar 

  87. Atre-Vaidya N, Taylor MA (1989) Effectiveness of lithium in schizophrenia: do we really have an answer? J Clin Psychiatry 50 (5): 170–173

    CAS  PubMed  Google Scholar 

  88. Small JG, Klapper MH, Malloy FW, Steadman TM (2003) Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 23 (3): 223–228

    Article  CAS  PubMed  Google Scholar 

  89. Schulz SC, Thompson PA, Jacobs M et al (1999) Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry 60 (6): 366–372

    CAS  PubMed  Google Scholar 

  90. Leucht S, McGrath J, Kissling W (2003) Lithium for schizophrenia. Cochrane Database Syst Rev (3): CD003834

    Google Scholar 

  91. Valevski A, Modai I, Lahav M, Weizman A (1993) Clozapine-lithium combined treatment and agranulocytosis. Int Clin Psychopharmacol 8 (1): 63–65

    Article  CAS  PubMed  Google Scholar 

  92. Garcia G, Crismon ML, Dorson PG (1994) Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol 14 (6): 426–428

    CAS  PubMed  Google Scholar 

  93. Chen B, Cardasis W (1996) Delirium induced by lithium and risperidone combination. Am J Psychiatry 153 (9): 1233–1234

    CAS  PubMed  Google Scholar 

  94. Peterson GA, Byrd SL (1996) Diabetic ketoacidosis from clozapine and lithium cotreatment. Am J Psychiatry 153 (5): 737–738

    CAS  PubMed  Google Scholar 

  95. Blier P, Slater S, Measham T, Koch M, Wiviott G (1998) Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol 13 (3): 137–140

    Article  CAS  PubMed  Google Scholar 

  96. Durrenberger S, de Leon J (1999) Acute dystonic reaction to lithium and risperidone. J Neuropsychiatry Clin Neurosci 11 (4): 518–519

    CAS  PubMed  Google Scholar 

  97. Owley T, Leventhal B, Cook EH, Jr (2001) Risperidone-induced prolonged erections following the addition of lithium. J Child Adolesc Psychopharmacol 11 (4): 441–442

    Article  CAS  PubMed  Google Scholar 

  98. Berry N, Pradhan S, Sagar R, Gupta SK (2003) Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. Pharmacotherapy 23 (2): 255–259

    Article  PubMed  Google Scholar 

  99. Ghaemi SN (2000) New treatments for bipolar disorder: the role of atypical neuroleptic agents. J Clin Psychiatry 61 [Suppl] 14: 33–42

    CAS  PubMed  Google Scholar 

  100. Luchins DJ (1984) Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. Am J Psychiatry 141 (5): 687–688

    CAS  PubMed  Google Scholar 

  101. Leucht S, McGrath J, White P, Kissling W (2002) Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev (3): CD001258

    Google Scholar 

  102. Gerson SL, Lieberman JA, Friedenberg WR et al (1991) Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 338 (8761): 262–263

    Article  CAS  PubMed  Google Scholar 

  103. Rittmannsberger H, Leblhuber F (1992) Asterixis induced by carbamazepine therapy. Biol Psychiatry 32 (4): 364–368

    Article  CAS  PubMed  Google Scholar 

  104. Rittmannsberger H, Leblhuber F, Sommer R (1991) Asterixis as a side effect of carbamazepine therapy. Klin Wochenschr 69 (6): 279–281

    Article  CAS  PubMed  Google Scholar 

  105. Müller T, Becker T, Fritze J (1988) Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 2 (8626–8627): 1500

    Article  PubMed  Google Scholar 

  106. Junghan U, Albers M, Woggon B (1993) Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? Pharmacopsychiatry 26 (6): 262

    Article  CAS  PubMed  Google Scholar 

  107. Basan A, Leucht S (2004) Valproate for schizophrenia. Cochrane Database Syst Rev (1): CD004028

    Google Scholar 

  108. Casey DE, Daniel DG, Wassef AA et al (2003) Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28 (1): 182–192

    Article  CAS  PubMed  Google Scholar 

  109. Haller E, Binder RL (1990) Clozapine and seizures. Am J Psychiatry 147 (8): 1069–1071

    CAS  PubMed  Google Scholar 

  110. Kando JC, Tohen M, Castillo J, Centorrino F (1994) Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 55 (6): 255–257

    CAS  PubMed  Google Scholar 

  111. Costello LE, Suppes T (1995) A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol 15 (2): 139–141

    Article  CAS  PubMed  Google Scholar 

  112. Wirshing WC, Ames D, Bisheff S et al (1997) Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol 17 (2): 120–121

    Article  CAS  PubMed  Google Scholar 

  113. Fisk GG, York SM (1987) The effect of sodium valproate on tardive dyskinesiarevisited. Br J Psychiatry 150: 542–546

    Article  CAS  PubMed  Google Scholar 

  114. Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM (1998) Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 31 (4): 122–125

    Article  CAS  PubMed  Google Scholar 

  115. Hesslinger B, Normann C, Langosch JM et al (1999) Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 19 (4): 310–315

    Article  CAS  PubMed  Google Scholar 

  116. Wassef AA, Dott SG, Harris A et al (2000) Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 20 (3): 357–361

    Article  CAS  PubMed  Google Scholar 

  117. Tiihonen J, Hallikainen T, Ryynanen OP et al (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54 (11): 1241–1248

    Article  CAS  PubMed  Google Scholar 

  118. Kremer I, Vass A, Gorelik I et al (2004) Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 56 (6): 441–446

    Article  CAS  PubMed  Google Scholar 

  119. Dursun SM, Devarajan S (2000) Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 45 (2): 198

    CAS  PubMed  Google Scholar 

  120. Levy E, Margolese HC, Chouinard G (2002) Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry 63 (11): 1045

    PubMed  Google Scholar 

  121. Navarro V, Pons A, Romero A, Bernardo M (2001) Topiramate for clozapine-induced seizures. Am J Psychiatry 158 (6): 968–969

    Article  CAS  PubMed  Google Scholar 

  122. Baynes D, Mulholland C, Cooper SJ et al (2000) Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res 45 (1–2): 47–56

    Article  CAS  PubMed  Google Scholar 

  123. Harrow M, Yonan CA, Sands JR, Marengo J (1994) Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 20 (2): 327–338

    CAS  PubMed  Google Scholar 

  124. Johnson DA (1988) The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 152: 320–323

    Article  CAS  PubMed  Google Scholar 

  125. Müller MJ, Wetzel H (1998) Dimensionality of depression in acute schizophrenia: a methodological study using the Bech-Rafaelsen Melancholia Scale (BRMES). J Psychiatr Res 32 (6): 369–378

    Article  PubMed  Google Scholar 

  126. Sands JR, Harrow M (1999) Depression during the longitudinal course of schizophrenia. Schizophr Bull 25 (1): 157–171

    CAS  PubMed  Google Scholar 

  127. Wassink TH, Flaum M, Nopoulos P, Andreasen NC (1999) Prevalence of depressive symptoms early in the course of schizophrenia. Am J Psychiatry 156 (2): 315–316

    CAS  PubMed  Google Scholar 

  128. Zisook S, McAdams LA, Kuck J et al (1999) Depressive symptoms in schizophrenia. Am J Psychiatry 156 (11): 1736–1743

    CAS  PubMed  Google Scholar 

  129. Häfner H (2004) Schizophrenie — von der Tradition zur Gegenwart. Neurotransmitter (4): 64–68

    Google Scholar 

  130. Peuskens J, Van Baelen B, De Smedt C, Lemmens P (2000) Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 15 (6): 343–349

    Article  CAS  PubMed  Google Scholar 

  131. Tandon R, Jibson MD (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology [Suppl] 28 (1): 9–26

    Article  CAS  Google Scholar 

  132. Tollefson GD, Sanger TM, Lu Y, Thieme ME (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55 (3): 250–258

    Article  CAS  PubMed  Google Scholar 

  133. Levinson DF, Umapathy C, Musthaq M (1999) Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 156 (8): 1138–1148

    CAS  PubMed  Google Scholar 

  134. Siris SG, Bermanzohn PC, Mason SE, Shuwall MA (1994) Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry 51 (2): 109–115

    CAS  PubMed  Google Scholar 

  135. Kirli S, Caliskan M (1998) A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res 33 (1–2): 103–111

    Article  CAS  PubMed  Google Scholar 

  136. Kasckow JW, Mohamed S, Thallasinos A et al (2001) Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. Int J Geriatr Psychiatry 16 (12): 1163–1167

    Article  CAS  PubMed  Google Scholar 

  137. Addington D, Addington J, Patten S et al (2002) Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 22 (1): 20–25

    Article  CAS  PubMed  Google Scholar 

  138. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A (1996) Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 153 (12): 1625–1627

    CAS  PubMed  Google Scholar 

  139. Arango C, Kirkpatrick B, Buchanan RW (2000) Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. J Nerv Ment Dis 188 (1): 50–53

    Article  CAS  PubMed  Google Scholar 

  140. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E (1995) A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 117 (4): 417–423

    Article  CAS  Google Scholar 

  141. Lee MS, Han CS, You YW, Kim SH (1998) Co-administration of sertraline and haloperidol. Psychiatry Clin Neurosci [Suppl] 52: 193–198

    Google Scholar 

  142. Lee MS, Kim YK, Lee SK, Suh KY (1998) A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 18 (5): 399–403

    Article  CAS  PubMed  Google Scholar 

  143. Takahashi H, Sugita T, Higuchi H, Shimizu T (2002) Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. Hum Psychopharmacol 17 (2): 95–98

    Article  CAS  PubMed  Google Scholar 

  144. Salokangas RK, Saarijarvi S, Taiminen T et al (1996) Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 94 (3): 175–180

    Article  CAS  PubMed  Google Scholar 

  145. Berk M, Ichim C, Brook S (2001) Efficacy of mirtazapine add-on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 16 (2): 87–92

    Article  CAS  PubMed  Google Scholar 

  146. Zoccali R, Muscatello MR, Cedro C et al (2004) The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 19 (2): 71–76

    Article  PubMed  Google Scholar 

  147. Anghelescu I, Szegedi A, Schlegel S et al (1998) Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. Eur Neuropsychopharmacol 8 (4): 315–320

    Article  CAS  PubMed  Google Scholar 

  148. Jockers-Scherübl MC, Bauer A, Godemann F et al (2005) Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol 20 (1): 27–31

    Article  PubMed  Google Scholar 

  149. Dequardo JR, Roberts M (1996) Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 153 (6): 840–841

    CAS  PubMed  Google Scholar 

  150. DuMortier G, Lochu A, Colen dM et al (1996) Elevated clozapine plasma concentrations after fluvoxamine initiation. Am J Psychiatry 153 (5): 738–739

    CAS  PubMed  Google Scholar 

  151. Hiemke C, Weigmann H, Härtter S et al (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14 (4): 279–281

    Article  CAS  PubMed  Google Scholar 

  152. Koponen HJ, Leinonen E, Lepola U (1996) Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 6 (1): 69–71

    Article  CAS  PubMed  Google Scholar 

  153. Wetzel H, Anghelescu I, Szegedi A et al (1998) Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18 (1): 2–9

    Article  CAS  PubMed  Google Scholar 

  154. Lammers CH, Deuschle M, Weigmann H et al (1999) Coadministration of clozapine and fluvoxamine in psychotic patients — clinical experience. Pharmacopsychiatry 32 (2): 76–77

    Article  CAS  PubMed  Google Scholar 

  155. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH (2004) Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65 (6): 766–771

    Article  CAS  PubMed  Google Scholar 

  156. Silver H (2001) Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7 (3): 283–304

    CAS  PubMed  Google Scholar 

  157. Silver H (2003) Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int Clin Psychopharmacol 18 (6): 305–313

    Article  PubMed  Google Scholar 

  158. Szegedi A, Wiesner J, Hiemke C (1995) Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 15 (2): 141–143

    Article  CAS  PubMed  Google Scholar 

  159. Szegedi A, Anghelescu I, Wiesner J et al (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32 (4): 148–153

    Article  CAS  PubMed  Google Scholar 

  160. Kuo FJ, Lane HY, Chang WH (1998) Extrapyramidal symptoms after addition of fluvoxamine to clozapine. J Clin Psychopharmacol 18 (6): 483–484

    Article  CAS  PubMed  Google Scholar 

  161. Olesen OV, Starup G, Linnet K (1996) Serious drug interaction between clozapine-Leponex and fluvoxamine-Fevarin. Ugeskr Laeger 158 (48): 6931–6932

    CAS  PubMed  Google Scholar 

  162. Weigmann H, Gerek S, Zeisig A et al (2001) Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 23 (4): 410–413

    Article  CAS  PubMed  Google Scholar 

  163. Raedler TJ, Jahn H, Arlt J et al (2004) Adjunctive use of reboxetine in schizophrenia. Eur Psychiatry 19 (6): 366–369

    Article  PubMed  Google Scholar 

  164. Wolkowitz OM (1993) Rational polypharmacy in schizophrenia. Ann Clin Psychiatry 5 (2): 79–90

    Article  CAS  PubMed  Google Scholar 

  165. Arana GW, Ornsteen ML, Kanter F et al (1986) The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Psychopharmacol Bull 22 (1): 77–87

    CAS  PubMed  Google Scholar 

  166. Carlsson A, Waters N, Waters S, Carlsson ML (2000) Network interactions in schizophrenia — therapeutic implications. Brain Res Rev 31 (2–3): 342–349

    Article  CAS  PubMed  Google Scholar 

  167. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148 (11): 1474–1486

    CAS  PubMed  Google Scholar 

  168. Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C (2002) Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 7 (1): 32–43

    Article  CAS  PubMed  Google Scholar 

  169. Ghaemi SN (2002) Polypharmacy in psychiatry. In: Oepen G (ed) Polypharmacy in Schizophrenia. Dekker, New York, p 101–132. Ref Type: Generic

    Google Scholar 

  170. Goff DC, Tsai G, Manoach DS et al (1996) D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153 (12): 1628–1630

    CAS  PubMed  Google Scholar 

  171. Goff DC, Henderson DC, Evins AE, Amico E (1999) A placebo-controlled cross-over trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45 (4): 512–514

    Article  CAS  PubMed  Google Scholar 

  172. Goff DC, Tsai G, Levitt J et al (1999) A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56 (1): 21–27

    Article  CAS  PubMed  Google Scholar 

  173. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC (2000) Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 157 (5): 826–828

    Article  CAS  PubMed  Google Scholar 

  174. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B (1999) Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 156 (1): 145–147

    CAS  PubMed  Google Scholar 

  175. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC (2004) High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55 (2): 165–171

    Article  CAS  PubMed  Google Scholar 

  176. Tuominen HJ, Tiihonen J, Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72 (2–3): 225–234

    Article  PubMed  Google Scholar 

  177. Berlant JL (1986) Neuroleptics and reserpine in refractory psychoses. J Clin Psychopharmacol 6 (3): 180–184

    Article  CAS  PubMed  Google Scholar 

  178. Meltzer HY (1992) Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 18 (3): 515–542

    CAS  PubMed  Google Scholar 

  179. Müller N, Riedel M, Scheppach C et al (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159 (6): 1029–1034

    Article  PubMed  Google Scholar 

  180. Harvey PD, Keefe RS (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158 (2): 176–184

    Article  CAS  PubMed  Google Scholar 

  181. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48 (5): 381–388

    Article  CAS  PubMed  Google Scholar 

  182. Freedman R, Hall M, Adler LE, Leonard S (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38 (1): 22–33

    Article  CAS  PubMed  Google Scholar 

  183. Friedman JI, Adler DN, Howanitz E et al (2002) A double blind placebo-controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51 (5): 349–357

    Article  CAS  PubMed  Google Scholar 

  184. Fukuzako H, Fukuzako T, Hashiguchi T et al (1999) Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. Am J Psychiatry 156 (8): 1205–1208

    CAS  PubMed  Google Scholar 

  185. Horrobin DF (1998) The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30 (3): 193–208

    Article  CAS  PubMed  Google Scholar 

  186. Mahadik SP, Evans D, Lal H (2001) Oxidative stress and role of antioxidant and omega-e essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 25 (3): 463–493

    Article  CAS  PubMed  Google Scholar 

  187. Pettegrew JW, Keshavan MS, Panchalingam K et al (1991) Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphrous 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 48 (6): 563–568

    CAS  PubMed  Google Scholar 

  188. Stanley JA, Williamson PC, Drost DJ et al (1994) Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study. Schizophr Res 13 (3): 209–215

    Article  CAS  PubMed  Google Scholar 

  189. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ (2002) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159 (9): 1596–1598

    Article  PubMed  Google Scholar 

  190. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK (2001) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49 (3): 243–251

    Article  CAS  PubMed  Google Scholar 

  191. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158 (12): 2071–2074

    Article  CAS  PubMed  Google Scholar 

  192. Strous RD, Maayan R, Lapidus R et al (2003) Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 60 (2): 133–141

    Article  CAS  PubMed  Google Scholar 

  193. Kane JM (1989) The current status of neuroleptic therapy. J Clin Psychiatry 50 (9): 322–328

    CAS  PubMed  Google Scholar 

  194. Arvanitis LA, Miller BG (1997) Multiple fixed doses of „Seroquel“ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42 (4): 233–246

    Article  CAS  PubMed  Google Scholar 

  195. Beasley CM Jr, Tollefson G, Tran P et al (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14 (2): 111–123

    Article  CAS  PubMed  Google Scholar 

  196. Marder SR (1992) Risperidone: clinical development: north American results. Clin Neuropharmacol [Suppl] 15: 1 Pt A: 92–93

    Google Scholar 

  197. Marder SR, Glynn SM, Wirshing WC et al (2003) Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 160 (8): 1405–1412

    Article  PubMed  Google Scholar 

  198. Tuunainen A, Wahlbeck K, Gilbody S (2002) Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 56 (1–2): 1–10

    Article  PubMed  Google Scholar 

  199. Bitter I, Dossenbach MR, Brook S et al (2004) Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28 (1): 173–180

    Article  CAS  PubMed  Google Scholar 

  200. Conley RR, Tamminga CA, Bartko JJ et al (1998) Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 155 (7): 914–920

    CAS  PubMed  Google Scholar 

  201. Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr (2003) The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol 23 (6): 668–671

    Article  CAS  PubMed  Google Scholar 

  202. Lindenmayer JP, Iskander A, Park M et al (1998) Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 59 (10): 521–527

    CAS  PubMed  Google Scholar 

  203. Bondolfi G, Dufour H, Patris M et al (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 155 (4): 499–504

    CAS  PubMed  Google Scholar 

  204. Sacchetti E, Panariello A, Regini C, Valsecchi P (2004) Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. Schizophr Res 69 (2–3): 325–331

    Article  PubMed  Google Scholar 

  205. Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the „right stuff“? Schizophr Bull 26 (1): 119–136

    CAS  PubMed  Google Scholar 

  206. Bilder RM, Goldman RS, Volavka J et al (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159 (6): 1018–1028

    Article  PubMed  Google Scholar 

  207. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159 (1): 103–108

    Article  PubMed  Google Scholar 

  208. Strasser O, Schmauss M, Messer T (2004) Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication. Psychiatr Prax [Suppl] 31 (1): 38–40

    Article  Google Scholar 

  209. Kilian R, Dietrich S, Toumi M, Angermeyer MC (2004) Quality of life in persons with schizophrenia in out-patient treatment with first-or second-generation antipsychotics. Acta Psychiatr Scand 110 (2): 108–118

    Article  CAS  PubMed  Google Scholar 

  210. Hertling I, Philipp M, Dvorak A et al (2003) Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology 47 (1): 37–46

    Article  CAS  PubMed  Google Scholar 

  211. Karow A, Naber D (2002) Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 162 (1): 3–10

    Article  CAS  Google Scholar 

  212. Ritsner M, Gibel A, Perelroyzen G et al (2004) Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 24 (6): 582–591

    Article  CAS  PubMed  Google Scholar 

  213. Voruganti L, Cortese L, Owyeumi L et al (2000) Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 43 (2–3): 135–145

    Article  CAS  PubMed  Google Scholar 

  214. Voruganti L, Cortese L, Owyeumi L et al (2002) Switching from conventional to novel antipsychotic drugs: results of aprospective naturalistic study. Schizophr Res 57 (2–3): 201–208

    Article  CAS  PubMed  Google Scholar 

  215. Hovens JE, Dries PJ, Melman CT, Wapenaar RJ, Loonen AJ (2005) Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, openlabel study. J Psychopharmacol 19 (1): 51–57

    Article  CAS  PubMed  Google Scholar 

  216. Lejeune J, Larmo I, Chrzanowski W et al (2004) Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. Int Clin Psychopharmacol 19 (5): 259–269

    Article  PubMed  Google Scholar 

  217. Zarate CA Jr, Daniel DG, Kinon BJ et al (1995) Algorithms for the treatment of schizophrenia. Psychopharmacol Bull 31 (3): 461–467

    PubMed  Google Scholar 

  218. Centorrino F, Goren JL, Hennen J et al (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161 (4): 700–706

    Article  PubMed  Google Scholar 

  219. Janssen B, Weinmann S, Berger M, Gaebel W (2004) Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 30 (4): 1023–1033

    PubMed  Google Scholar 

  220. Miller AL, Crismon ML, Rush AJ et al (2004) The Texas medication algorithm project: clinical results for schizophrenia. Schizophr Bull 30 (3): 627–647

    PubMed  Google Scholar 

  221. Szegedi A, Anghelescu I, Wiesner J et al (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32 (4): 148–153

    Article  CAS  PubMed  Google Scholar 

  222. Lammers CH, Deuschle M, Weigmann H et al (1999) Coadministration of clozapine and fluvoxamine in psychotic patients — clinical experience. Pharmacopsychiatry 32 (2): 76–77

    Article  CAS  PubMed  Google Scholar 

  223. Hiemke C, Weigmann H, Härtter S et al (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14 (4): 279–281

    Article  CAS  PubMed  Google Scholar 

  224. Abu-Tair F, Kopitz J, Bergemann N (2006) Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol 26: 669–71

    Article  PubMed  Google Scholar 

  225. Afshar H, Roohafza H, Mousavi G et al (2008) Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol epub ahead

    Google Scholar 

  226. Amiri A, Noorbala AA, Nejatisafa AA et al (2008) Efficacy of selegiline add-on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Hum Psychopharmacol 23: 79–86

    Article  CAS  PubMed  Google Scholar 

  227. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G (2008) Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 41: 24–28

    Article  CAS  PubMed  Google Scholar 

  228. Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO (2005) Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry 162: 388–90

    Article  PubMed  Google Scholar 

  229. Chakos MH, Glick ID, Miller AL et al (2006) Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 57: 1094–101

    Article  PubMed  Google Scholar 

  230. Chang JS, Ahn YM, Park HJ et al (2008) Aripiprazole augmentation in clozapinetreated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69: 720–731

    Article  CAS  PubMed  Google Scholar 

  231. Citrome L, Jaffe A, Levine J, Allingham B, Robinson J (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 55: 1006–13

    Article  PubMed  Google Scholar 

  232. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S (2008) Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophr Bull epub ahead

    Google Scholar 

  233. Englisch S, Zink M (2008) Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 32: 1386–92

    Article  CAS  PubMed  Google Scholar 

  234. Faries D, Ascher-Svanum H, Zhu B, Correll C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5: 26

    Article  PubMed  Google Scholar 

  235. Fehr C (2006) For: is monotherapy the gold standard of psychopharmacology? Psychiatr Prax 33: 207–8

    Article  PubMed  Google Scholar 

  236. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC (2007) Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 92: 90–94

    Article  PubMed  Google Scholar 

  237. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry 65: 1377–88

    Article  PubMed  Google Scholar 

  238. Genc Y, Taner E, Candansayar S (2007) Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 24: 1–13

    Article  CAS  PubMed  Google Scholar 

  239. Glick ID, Pham D, Davis JM (2006) Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia. J Clin Psychiatry 67: 1261–65

    Article  CAS  PubMed  Google Scholar 

  240. Goff DC, Keefe R, Citrome L et al (2007) Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 27: 582–89

    Article  CAS  PubMed  Google Scholar 

  241. Gupta S, Droney T, Kyser A, Keller P (1999) Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Compr Psychiatry 40: 148–50

    Article  CAS  PubMed  Google Scholar 

  242. Henderson DC, Kunkel L, Nguyen DD et al (2006) An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 113: 142–47

    Article  CAS  PubMed  Google Scholar 

  243. Honer WG, Thornton AE, Chen EY et al (2006) Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354: 472–82

    Article  CAS  PubMed  Google Scholar 

  244. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188: 122–27

    Article  PubMed  Google Scholar 

  245. Karunakaran K, Tungaraza TE, Harborne GC (2007) Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 21: 453–56

    Article  CAS  PubMed  Google Scholar 

  246. Mossaheb N, Spindelegger C, Asenbaum S, Fischer P, Barnas C (2008) Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine. World J Biol Psychiatry epub ahead

    Google Scholar 

  247. Paton C, Whittington C, Barnes TR (2007) Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 27: 198–204

    Article  CAS  PubMed  Google Scholar 

  248. Risch SC, Horner MD, McGurk SR et al (2007) Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. Schizophr Res 93: 131–35

    Article  PubMed  Google Scholar 

  249. Rummel C, Kissling W, Leucht S (2006) Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev 3: CD005581

    Google Scholar 

  250. Sepehry AA, Potvin S, Elie R, Stip E (2007) Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 68: 604–10

    Article  CAS  PubMed  Google Scholar 

  251. Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandol E (2007) The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 31: 1493–99

    Article  CAS  PubMed  Google Scholar 

  252. Stoner SC, Dahmen MM, Berges A, Petry WM (2007) Augmentationof aripiprazole with low-dose clozapine. Pharmacotherapy 27: 1599–602

    Article  CAS  PubMed  Google Scholar 

  253. Suzuki T, Uchida H, Watanabe K et al (2008) Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol epub ahead

    Google Scholar 

  254. Volz A, Khorsand V, Gillies D, Leucht S (2007) Benzodiazepines for schizophrenia. Cochrane Database Syst Rev CD006391

    Google Scholar 

  255. Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS (2007) Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 40: 47–52

    Article  CAS  PubMed  Google Scholar 

  256. Ziegenbein M, Kropp S, Kuenzel HE (2005) Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 28: 220–224

    Article  CAS  PubMed  Google Scholar 

  257. Ziegenbein M, Wittmann G, Kropp S (2006) Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Investig 26: 117–24

    Article  CAS  PubMed  Google Scholar 

  258. Zink M, Kuwilsky A, Krumm B, Dressing H (2008) Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol epub ahead

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bezirkskliniken Schwaben, Bezirkskrankenhaus Augsburg, Dr.-Mack-Straße 1, 86156, Augsburg, Deutschland

    PD Dr. med. Thomas Messer, Dr. med. Cordula Tiltscher & Prof. Dr. med. Max Schmauss

Authors
  1. PD Dr. med. Thomas Messer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. Cordula Tiltscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. Max Schmauss
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag/Wien

About this chapter

Cite this chapter

Messer, T., Tiltscher, C., Schmauss, M. (2009). Polypharmazie in der Behandlung der Schizophrenie. In: Polypharmazie in der Behandlung psychischer Erkrankungen. Springer, Vienna. https://doi.org/10.1007/978-3-211-79826-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-79826-3_2

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-79825-6

  • Online ISBN: 978-3-211-79826-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation